WHY IT MATTERS: If thin-film CBD delivery is confirmed to offer superior and more consistent bioavailability compared to traditional oral products, patients may need to recalibrate their doses when switching formats to avoid unintended underdosing or overdosing. CLINICAL OVERVIEW: Sublingual and buccal thin-film delivery systems represent a meaningful departure from conventional oral cannabinoid formats because they bypass first-pass hepatic metabolism, potentially improving both the speed of onset and the consistency of systemic absorption. CBD delivered through mucoadhesive strip technology may achieve higher bioavailability compared to standard oil-based or capsule formulations, which are notoriously variable due to differences in fed versus fasted states and individual digestive physiology.